Ann: Partnership For Allogeneic Cell-based Cancer Immunotherapies, page-27

Do not miss the real impact of this announcement.

Too easy to be distracted by the hope that this research will lead to a blockbuster cancer killer at affordable prices.  That might happen.  Some day and much later.  After several phases of trials and jumping through regulatory hoops.  And if there is not effective competition.  A gauntlet of maybes to run and a long timeframe to payday.

The real booster to MSB investor spirits is the quality of the partners.  Hudson plus Monash plus Prof. Alan Trounson.  And Australian Government funding.  Hudson and Monash and Trounson need a stem cell provider to supply the necessary vehicle for their research.  They could have chosen any producer in the world.  They would have no regard for country of origin; being Oz was no help to MSB.  And it's not supportive old mates like endlessly tolerant A. Waislitz (well, almost endlessly.  Let's see if he can wreak much needed board change).  No, they chose MSB because it's world's best.  Best in product.  Best in production.  They don't take second best.  They would not allow their opportunity to produce ground breaking research to be handicapped by an inferior partner.

This is a colossal affirmation of MSB's stem cells.  Impossible to overestimate the significance.

Peer review multiplied.